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S U M M A R Y
Background: The relationship between the hospital use of various classes of antibiotics and resistance of
Escherichia coli to quinolones remains debated. Our aim was to study the relationship between the
hospital use of 16 classes of antibacterial agents and the incidence of quinolone-resistant E. coli isolates.
Methods: Antibiotic use and resistance data were collected from 36 hospitals. Incident rate ratios (IRR)
were assessed using negative binomial regression.
Results: The incidence of quinolone-resistant isolates was independently associated with the
consumption of tetracyclines (IRR 1.139, 95% CI 1.030–1.259), ﬁrst- and second-generation
cephalosporins (IRR 1.007, 95% CI 1.002–1.013), third-generation cephalosporins (IRR 1.029, 95% CI
1.010–1.048), and quinolones (IRR 1.007, 95% CI 1.000–1.014). These associations were independent
from the type of patient served.
Conclusions: The level of hospital use of quinolones inﬂuences the incidence of quinolone resistance in E.
coli hospital isolates. The consumption of two other classes of antibiotics, cephalosporins and
tetracyclines, is also associated with quinolone resistance.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Conﬂicting results have been published on the relationship
between the hospital use of antibacterial agents and resistance to
quinolones in Escherichia coli hospital isolates, partly because
inappropriate statistical methods have been used to study this
issue. Statistical methods suited to the analysis of the relationship
between antibiotic use and resistance include time series analysis
and to a lesser extent cross-sectional studies.1,2 Conversely, it is not
appropriate to use correlation or linear regression on time series.1,2
Most previous studies have focused on the relationship between
the use of quinolones and resistance to quinolones. If we only
consider studies based on either time series analysis or a cross-
sectional design, the relationship between the hospital use of
quinolones and quinolone resistance in E. coli remains insufﬁ-
ciently proven, as three studies have found a statistically
signiﬁcant association and two have not.2–6 Firm conclusions
cannot be drawn from other studies that have analyzed time series
using correlation or linear regression.7–10* Corresponding author. Tel./Fax: +33 240 412 854.
E-mail address: eric.batard@chu-nantes.fr (E. Batard).
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http://dx.doi.org/10.1016/j.ijid.2012.10.005Moreover, the relationship between quinolone resistance and
the use of other classes of antibiotics has been poorly investigated.
Indeed, one study demonstrated a relationship between quinolone
resistance and the use of quinolones, piperacillin/tazobactam, and
carbapenems in univariate analysis, but without testing the
independence of these associations.4 Firm conclusions cannot be
drawn from other studies that have analyzed time series using
correlation analysis.8,10 Hence, the inﬂuence of the hospital use of
various classes of antibacterial agents on resistance of E. coli to
quinolones has to be established with more certainty. This debate
is crucial, because if antimicrobial consumption really inﬂuences
resistance to quinolones in E. coli, it implies that antimicrobial
restrictions in hospitals may help to control it. In this study, we
aimed to assess the relationship between the hospital use of
various classes of antibiotics and quinolone resistance in E. coli
isolates in a network of 36 hospitals.
2. Methods
Antibiotic use and resistance data were collected from 36 acute
care hospitals of the Pays de la Loire region, France, during the year
2009. Antibiotic quantities were converted to deﬁned daily dosesses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Distribution of total antibiotic use in 36 hospitals.
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the World Health Organization Collaborating Centre for Drug
Statistics Methodology (http://www.whocc.no). Antibacterial
agents were grouped into 16 classes, adapted from the Anatomical
Therapeutic Chemical (ATC) classiﬁcation system: (1) beta-
lactamase-resistant penicillins (J01CF), (2) amoxicillin (J01CA04)
(ampicillin is not commercially available in France), (3) amoxicil-
lin/ampicillin and enzyme inhibitor (J01CR01 and J01CR02), (4)
ticarcillin and piperacillin with or without enzyme inhibitor
(J01CA12, J01CA13, J01CR03, J01CR05), (5) ﬁrst- and second-
generation cephalosporins (J01DB, J01DC), (6) third-generation
cephalosporins (J01DD) excluding ceftazidime, (7) anti-pseudo-
monal cephalosporins including ceftazidime (J01DD02) and
fourth-generation cephalosporins (J01DE), (8) carbapenems
(J01DH), (9) tetracyclines (J01A), (10) sulfonamides and trimetho-
prim (J01E), (11) macrolides, lincosamides, and streptogramins
(J01F), (12) aminoglycosides (J01G), (13) quinolones (J01 M), (14)
glycopeptides (J01XA), (15) imidazole derivatives (J01XD), and
(16) other antibacterial agents.
Each participating hospital provided the number of non-
duplicate E. coli isolates from all clinical sites (e.g., blood and
urine) and all hospital units, and the number of pathogens with
resistance to nalidixic acid. Duplicate isolates were deﬁned on the
basis of two criteria: (1) culture from the same patient during the
study period, and (2) identical pattern of susceptibility to
amoxicillin, co-amoxiclav, ceftriaxone, co-trimoxazole, and nali-
dixic acid. The incidence density of resistant isolates was
calculated as the ratio of the number of resistant isolates to the
number of patient-days in the whole hospital. Susceptibility tests
were done and interpreted as recommended by the French Society
for Microbiology 2009 guidelines (http://www.sfm-microbiolo-
gie.org/UserFiles/ﬁle/CASFM/casfm_2009-1.pdf). Non-susceptibil-
ity to quinolones was deﬁned by a minimum inhibitory
concentration (MIC) of nalidixic acid >16 mg/l or an inhibition
diameter <15 mm. Non-susceptibility to ceftriaxone was deﬁned
by a MIC >2 mg/l or inhibition diameter <23 mm.
Descriptive statistics were expressed as the median with 25th–
75th percentiles (interquartile range, IQR). The structure of
antimicrobial use was analyzed using principal component
analysis (PCA). The relationship between antibiotic use and the
incidence density of resistant isolates was assessed using negative
binomial regression. Results were expressed as the incident rate
ratio (IRR), which is the relative risk of incidence density between
two hospitals that differ by 1 DDD/1000 patient-days. RRmax was
deﬁned as IRRd, where d is the difference between the maximal and
minimal consumptions of the considered antibacterial class. The
relationship between the incidence density of resistance and the
use of every class of antibacterial agent was tested in univariate
analysis. Then, with the same type of regression model, we
conducted a multivariable analysis on antibiotic classes that were
associated (p  0.10) with resistance in the univariate analysis.
Signiﬁcant classes of antibacterial agents were selected by a
backward procedure with an a threshold ﬁxed to 5%. The statistical
analysis was performed using R software, version 2.14.2011-12-16
(http://CRAN.R-project.org).
3. Results
The median number of hospital beds was 214 (IQR 145–373). The
cumulated number of patient-days was 4 212 540 during the year
2009. The median percentages of patient-days for each hospital were
distributed across the following activities: medical 23.5% (IQR 0–
33.8%), surgical 17.0% (IQR 2.6%–55.9%), critical care 0 (IQR 0–1.2%),
pediatrics 0 (IQR 0–2.3%), obstetrics 5.0% (IQR 0–8.0%), rehabilitation
12.3% (IQR 0–24.8%), long-term care 0 (IQR 0–19.5%), and psychiatry
0 (IQR 0–0). The median number of patient-days per hospital was63 440 (IQR 42 898–113 984). Antibiograms of 23 614 isolates were
collected. The median number of isolates per hospital was 285 (IQR
139–570). The median percentage of quinolone-resistant E. coli
(QREC) was 15.3% (IQR 11.1–17.9%) and the median incidence
density of QREC was 0.66 isolates/1000 patient-days (IQR 0.38–
0.97). Total antibiotic use ranged from 145.1 to 615.6 DDD/1000
patient-days (Figure 1). The consumption of antibacterial agents is
reported in Table 1. The structure of consumption of 16 classes of
antimicrobials was analyzed using PCA (Figure 2). The score plot
(Figure 2A) showed that our study sample was rather homogeneous.
First and second principal components explained 51.1% and 18.7%,
respectively, of total observed variance, and were mostly associated
with the use of amoxicillin/ampicillin  enzyme inhibitor, imida-
zoles, quinolones, aminoglycosides, ﬁrst- and second-generation
cephalosporins, third-generation cephalosporins, macrolides, lincosa-
mides, and streptogramins, and amoxicillin (Figure 2B).
In univariate analysis, the incidence of QREC was signiﬁcantly
associated with the use of eight different classes of antibiotics:
amoxicillin/ampicillin with enzyme inhibitor, ﬁrst- and second-
generation cephalosporins, third-generation cephalosporins, tetra-
cyclines, aminoglycosides, quinolones, glycopeptides, and imida-
zoles (Table 2). Four antibacterial classes remained independently
associated with the incidence of QREC isolates: tetracyclines, ﬁrst-
and second-generation cephalosporins, third-generation cephalos-
porins, and quinolones (Table 3). Using the model, the baseline
incidence (i.e., in a theoretical hospital without the use of any of
these classes) would be 0.22 QREC isolates for 1000 patient-days.
Using the example of quinolone use, the IRR should be interpreted as
follows: the incidence of QREC increases by 1.0072-fold when the
quinolone use increases by 1 DDD/1000 patient-days. RRmax should
be considered as the relative risk of incidence density between the
hospitals with the highest and lowest consumption. For instance, the
relative risk of QREC incidence was 2.7 for quinolone use.
Additionally, we checked if the incidence of QREC was a
function of the type of patient served. First, we tested the
relationship between the incidence of QREC and the percentage of
patients-days in eight different activities (medical, surgical,
pediatrics, obstetrics, critical care, rehabilitation, long-term care,
and psychiatry) using negative binomial regression. In univariate
analysis, three activities – surgical, rehabilitation, and long-term
care – were linked with the incidence of QREC at p  0.10. These
variables were added to the eight classes of antibiotics previously
selected for the multivariable analysis. The ﬁnal model did not
retain any type of activity. Thus, the links between the incidence of
QREC and the use of tetracyclines, ﬁrst- and second-generation
Table 1
Use of the main classes of antibacterial agents in 36 hospitals
Class Median consumption (IQR),
DDD/1000 patient-days
beta-Lactamase-resistant penicillins 7.67 (3.83–12.18)
Amoxicillin 52.43 (34.20–74.95)
Amoxicillin/ampicillin + EI 124.67 (81.19–146.81)
Ticarcillin/piperacillin  EI 0.41 (0–2.25)
First- and second-generation cephalosporins 14 (1.02–41.43)
Third-generation cephalosporinsa 14.34 (7.14–19.79)
Anti-pseudomonal cephalosporins 0.58 (0.20–1.96)
Carbapenems 1.37 (0.29–2.61)
Tetracyclines 0.8 (0.18–1.65)
Sulfonamides 3.68 (1.87–5.31)
Macrolides, lincosamides, streptogramins 12.38 (9.58–16.13)
Aminoglycosides 7.44 (3.54–16.74)
Quinolones 47.05 (33.04–56.03)
Glycopeptides 2.42 (1.37–4.35)
Imidazoles 10.94 (4.87–17.09)
Other antibiotics 7.61 (5.02–15.96)
Total antibiotic use 334.1 (257.76–386.72)
DDD, deﬁned daily dose; EI, enzyme inhibitor; IQR, interquartile range.
a Excluding ceftazidime.
Figure 2. Principal component analysis of the use of 16 antimicrobial classes in 36
hospitals. (A) Score plot of ﬁrst and second principal components; each point
represents a hospital. (B) Correlation loading plot of ﬁrst and second principal
components, showing the correlation between antimicrobial use and principal
component scores; the outer and inner circles indicate 100% and 50% explained
variance, respectively. (BLResPen, beta-lactamase-resistant penicillins; PenA,
amoxicillin; PenA + Inh, amoxicillin/ampicillin and enzyme inhibitor; CUP,
ticarcillin and piperacillin with or without enzyme inhibitor; C1G + C2G, ﬁrst-
and second-generation cephalosporins; C3G*, third-generation cephalosporins
excluding ceftazidime; AntiPs cep, anti-pseudomonal cephalosporins; Penems,
carbapenems; Tetr, tetracyclines; Sulf, sulfonamides and trimethoprim; MLS,
macrolides, lincosamides, and streptogramins; Aminogl, aminoglycosides; Quinol,
quinolones; Glyco, glycopeptides; Imid, imidazole derivatives; Other, other
antibacterial agents.).
E. Batard et al. / International Journal of Infectious Diseases 17 (2013) e254–e258e256cephalosporins, third-generation cephalosporins, and quinolones
were independent from the type of patient served.
The use of third-generation cephalosporins is a known risk
factor for resistance to ceftriaxone, and we conﬁrmed this with our
own data (data not shown).2,4,10,11 Furthermore, there was a
strongly signiﬁcant association between resistance to ceftriaxone
and resistance to quinolones (p < 0.0001). Therefore, we con-
structed a new model, including the use of tetracyclines, ﬁrst- and
second-generation cephalosporins, third-generation cephalospor-
ins, and quinolones, and resistance to ceftriaxone as predictors,
and resistance to quinolones as the predicted variable. The
consumption of ﬁrst- and second-generation cephalosporins and
the use of third-generation cephalosporins remained signiﬁcantly
associated with resistance to quinolones, independently from the
incidence of resistance to ceftriaxone.
4. Discussion
Resistance to nalidixic acid was selected as a marker of
resistance to quinolones, because it is the ﬁrst step before
resistance to ﬂuoroquinolones.12 Resistance rates to nalidixic acid
and to ciproﬂoxacin were signiﬁcantly correlated in our study
sample (Pearson’s R = 0.83, p < 0.0001). Resistance to nalidixic acid
is clinically relevant in France, as French guidelines recommend
not treating urinary tract infections with any ﬂuoroquinolone if the
isolate is resistant to nalidixic acid but susceptible to ﬂuoroqui-
nolones, to limit the risk of selecting ﬂuoroquinolone-resistant
mutants during therapy.13
We found that the incidence of QREC isolates was indepen-
dently associated with the hospital use of quinolones. This result is
in accordance with three previous studies.3,4,6 Another study in the
USA used the same design as ours and found no correlation
between the hospital use of quinolones in 17 hospitals and the
resistance rate to quinolones.5 Different statistical power may
account for the discrepancy with our study, as we used a larger
panel of hospitals. Consequently, we consider that the level of
hospital use of quinolones convincingly inﬂuences the incidence of
quinolone resistance in E. coli hospital isolates.
The relationship between QREC and extended-spectrum
cephalosporin use in the hospital setting has previously been
suggested.10 We also found that the incidence of QREC was
associated with third-generation cephalosporin use. This relation-
ship persisted independently from the incidence of resistance toceftriaxone. However, our study was not designed to demonstrate
causality. As E. coli are less often resistant to third-generation
cephalosporins than to quinolones, infections due to QREC may be
treated with third-generation cephalosporins. Hence, the use of
third-generation cephalosporins might be higher because the
incidence of QREC has increased. Additional studies using time
series analysis are needed to clarify this issue.
Conversely, ﬁrst- and second-generation cephalosporins and
tetracyclines are not used to treat infections due to QREC. Hence,
our study suggests that these two classes of antibiotics may also
select for resistance to quinolones in E. coli hospital isolates.
Resistance to tetracyclines is not routinely tested in E. coli hospital
isolates. However, resistance to quinolones is plausibly associated
with resistance to tetracyclines, and this may explain why the use
of tetracyclines is linked to the incidence of QREC.
Surprisingly, the effect of quinolone use on QREC incidence –
expressed as the IRR – was not higher than the effect of other
classes selected in the ﬁnal model. Indeed, the QREC incidence
Table 2
Univariate analysis of the relationship between hospital use of major classes of
antibacterial agents and incidence of quinolone-resistant E. coli isolates
Class IRR (95% CI) Pearson’s
Rho
beta-Lactamase-
resistant penicillins
1.0112 (0.9807–1.0427) 0.1084
Amoxicillin 1.0018 (0.9946–1.0091) 0.0719
Amoxicillin/ampicillin + EI 1.0054 (1.0011–1.0098) 0.3941
Ticarcillin/piperacillin  EI 1.0124 (0.9280–1.1044) 0.0290
First- and second-generation
cephalosporins
1.0079 (1.0012–1.0146) 0.4289
Third-generation cephalosporinsa 1.0461 (1.0254–1.0671) 0.4981
Anti-pseudomonal cephalosporins 1.0419 (0.9598–1.1311) 0.1387
Carbapenems 1.0438 (0.9789–1.1129) 0.1673
Tetracyclines 1.1627 (1.0259–1.3177) 0.3480
Sulfonamides 1.0003 (0.9646–1.0373) 0.0107
Macrolides, lincosamides,
streptogramins
1.0090 (0.9759–1.0432) 0.0782
Aminoglycosides 1.0415 (1.0218–1.0616) 0.5946
Quinolones 1.0140 (1.0059–1.0220) 0.5567
Glycopeptides 1.0611 (1.0155–1.1088) 0.4424
Imidazoles 1.0484 (1.0248–1.0725) 0.5243
Other antibiotics 1.0161 (0.9957–1.0368) 0.2200
CI, conﬁdence interval; EI, enzyme inhibitor; IRR, incidence rate ratio. Incident rate
ratios were computed using negative binomial regression; correlations between the
incidence of quinolone-resistant E. coli and antibiotic use were also analyzed using
Pearson’s method.
a Excluding ceftazidime.
Table 3
Multivariable analysis of the relationship between hospital use of major classes of
antibacterial agents and incidence of quinolone-resistant E. coli isolates
IRR (95% CI) RRmaxa
First- and second-generation
cephalosporins
1.0072 (1.0019–1.0126) 2.3
Third-generation cephalosporinsb 1.0287 (1.0095–1.0482) 2.9
Tetracyclines 1.1387 (1.0296–1.2594) 2.1
Quinolones 1.0072 (1.0001–1.0144) 2.7
CI, conﬁdence interval; IRR, incidence rate ratio. The pseudo-R2 was 0.07.
a RRmax = IRRd, where d is the difference between the maximal and minimal
consumptions of the considered antibacterial class.
b Excluding ceftazidime.
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for quinolones and tetracyclines, increased by 1.0072 and 1.1387,
respectively. However, as tetracyclines were far less used than
quinolones and cephalosporins, the effects of the four classes in the
ﬁnal model – expressed as RRmax – were roughly similar, ranging
from 2.1 to 2.9.
Our study sample included all private and public acute care
hospitals of an administrative region of 3 500 000 inhabitants,
providing various types of care, e.g., mostly medical, mostly
surgical, mostly obstetric, or mixed activities. The relationship
between QREC and the consumption of cephalosporins, quino-
lones, and tetracyclines remained after taking into account the
type of patient served, thus reinforcing our results.
Our study has several limitations. First, as discussed above, our
cross-sectional design can demonstrate an association between
antimicrobial use and resistance, but not causality. Second, we
cannot be sure that hospitals are totally independent entities, as
they may share some clinical practice guidelines, opinion leaders,
and patients. However, hospitals in this study were totally
independent from an administrative point of view, and showed
great variations in the types of patient served and antimicrobial
consumption. Third, our model explained a limited fraction of thevariability of the incidence of QREC. We consider that the risk of
over-ﬁtting the model was acceptable, considering the ratio
between sample size and number of predictors, the conﬁdence
intervals of the IRRs, the values of RRmax, and the biological
plausibility of our results. Fourth, we could not exclude communi-
ty-acquired isolates from our data. However, the inclusion of
community-acquired isolates would probably lead to an under-
estimate of the magnitude of the association between hospital use
of antimicrobials and bacterial resistance. Hence, our conclusions
should remain acceptable.
It has previously been shown that restricting the community
use of ciproﬂoxacin is associated with a decreased resistance rate
of E. coli to quinolones in the community.14 Furthermore, a 2-year
intervention that decreased the hospital use of quinolones reduced
the rate of resistance to quinolones in E. coli in a stepwise manner,
although it was unable to reverse the increasing trend of resistance
during the intervention.15 Longer interventions may be necessary
to decrease the incidence of QREC in hospitals. Moreover, if future
studies designed for causation conﬁrm that quinolone resistance in
E. coli is at least partly due to the hospital use of cephalosporins or
tetracyclines, interventions aimed at decreasing the incidence of
QREC by restricting antibiotic use may have to take into account
every involved class of antimicrobials.
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